Choosing Among Dual Orexin Receptor Antagonists

Choosing Among Dual Orexin Receptor Antagonists

Generated November 2026 · Clinical Deep Dive0 CommentsA clinician choosing among suvorexant, lemborexant, and daridorexant for a patient with insomnia faces three similar-looking tablets and a trial record built on placebo comparisons. Each agent's pivotal trials compared it with placebo, and one lemborexant trial added zolpidem extended release as an active comparator. Biol Psychiatry +2 The starting doses alone differ: 10 mg for Belsomra, 5 mg for Dayvigo, and 25 mg for Quviviq. Belsomra PI +2 Interaction rules split as well: the same moderate CYP3A inhibitor calls for a dose cap with Belsomra and Quviviq but avoidance with Dayvigo. Belsomra PI +2 Choosing between them therefore depends on dosing ladders, elimination, interaction rules, and next-day risk, and not on head-to-head efficacy data.The American Academy of Sleep Medicine (AASM) 2017 pharmacologic guideline addresses suvorexant alone among the dual orexin receptor antagonists (DORAs), with a weak recommendation for sleep maintenance insomnia based on low-quality evidence. J Clin Sleep Med The 2023 European guideline allows orexin receptor antagonists for up to 3 months, or longer in some cases. J Sleep Res A 2026 meta-analysis found no significant increase in falls with DORA use across 19 studies, yet its authors cautioned that the data fell short of the optimal information size, the minimum number of events needed to detect a clinically meaningful effect. J Am Geriatr SocDaytime impairment is the practical stake, because all three labels warn that these drugs can impair next-day alertness and that older patients face a higher risk of falls. Belsomra PI +2 Nor is cognitive behavioral therapy for insomnia (CBT-I), the first-line option, easy to obtain: only about 825 clinicians are listed in the International CBT-I Provider Directory. Medscape That leaves many patients and clinicians weighing a drug choice with few firm anchors.This Deep Dive sets the three approved agents side by side. It covers where dosing, kinetics, and interactions diverge, what each label says about next-day impairment, and where the evidence supports choosing one agent over another. It closes with the agents and regulatory changes on the horizon.9.8% vs 7.7%Dayvigo 10 mg somnolence in patients 65 and older versus younger patients, alongside the label’s caution above 5 mg in older adults. Dayvigo PIOdds ratio (OR) 0.76 (95% CI 0.56 to 1.04)Pooled odds of falls with DORAs versus non-use across 19 studies; the evidence did not meet the optimal information size. J Am Geriatr Soc1 of 3DORAs addressed by the 2017 AASM pharmacologic guideline, with a weak recommendation for sleep maintenance insomnia only. J Clin Sleep MedDEEP DIVE:Choosing Among Three Dual Orexin Receptor AntagonistsMedscape Medical News © 2026 WebMD, LLCSend comments and news tips to news@medscape.net. Cite this: Three Orexin Antagonists, No Head-to-Head Trials: How to Choose a DORA for Insomnia - Medscape- November 17, 2026.

Original Source

Read the full article at Medscape →

KhanList aggregates and links to publicly available news content. We do not host full articles from third-party sources. Always verify important information with original sources.